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OBJECTIVE: Leukocyte-associated immunoglobulin-like receptor-1 is an inhibitory receptor primarily expressed
by immune cells. This study was undertaken to define the role of this molecule in osteoclast differentiation and
rheumatoid arthritis.
METHODS: In vitro osteoclast assays were performed to characterize the role of Leukocyte-associated
immunoglobulin-like receptor-1 in murine and human osteoclastogenesis. Human Leukocyte-associated
immunoglobulin-like receptor-1 expression was assessed by immunohistochemistry staining in the synovium
of patients with rheumatoid arthritis. The levels of soluble Human Leukocyte-associated immunoglobulin-like
receptor-1 were determined by enzyme-linked immunosorbent assay.
RESULTS: We found that multinucleated osteoclast formation from mouse bone marrow cells was inhibited by
treatment with a monoclonal antibody against mouse Leukocyte-associated immunoglobulin-like receptor-1 in
vitro. By immunohistochemistry, we found that Leukocyte-associated immunoglobulin-like receptor-1 was
mainly expressed by macrophages in the inflamed synovial tissue of rheumatoid arthritis patients. In addition,
serum and synovial fluid levels of soluble Leukocyte-associated immunoglobulin-like receptor-1 were higher in
rheumatoid arthritis patients compared to healthy controls or osteoarthritis patients. Moreover, overexpression
of Leukocyte-associated immunoglobulin-like receptor-1 in CD14+ monocytes from healthy volunteers also
inhibited human osteoclastogenesis.
CONCLUSION: Collectively, these data demonstrate for the first time that Leukocyte-associated immunoglo-
bulin-like receptor-1 inhibits osteoclastogenesis. Therefore, these results may have therapeutic implications for
the treatment of rheumatoid arthritis.
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& INTRODUCTION
Osteoclasts (OCs), the only cell type capable of resorbing
bone, are derived from bone marrow (BM) precursor cells
of the monocyte-macrophage lineage (1). The disruption
of the dynamic balance of the osteoblasts and OCs leads
to pathological bone resorption, such as that observed
in rheumatoid arthritis (RA) (2). It is well known that
co-stimulatory signals generated by transmembrane immu-
noreceptors can cooperate to induce OC differentiation.
Immunoglobulin (Ig)-like receptors, initially identified and
well studied in the immune system, are a novel class of
receptors that are critically involved in the regulation of
bone homeostasis (3,4). Several studies have specifically
suggested critical roles for Ig-like receptors of the leukocyte
receptor complex (LRC)-encoded family in the control of
osteoclastogenesis, such as the activatory receptors OC-
associated receptor (OSCAR) and paired immunoglobulin-
like receptor B (PIR-B).
Leukocyte-associated immunoglobulin-like receptor-1
(LAIR-1) is an LRC-encoded transmembrane glycoprotein
containing two immunoreceptor tyrosine-based inhibition
motifs (ITIMs) in its cytoplasmic tail. LAIR-1 is broadly
expressed on cells in the immune system, including natural
killer (NK) cells, T cells, B cells, monocytes, and dendritic
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cells, as well as CD34+ hematopoietic progenitors (5,6). This
receptor can inhibit the cytotoxicity of NK cells (activated
lymphocyte killer cells) as well as the differentiation of
blood precursors into dendritic cells (7-9). Mouse orthologs
of human LAIR-1 (hLAIR-1) share ,40% protein sequence
identity and the potent inhibitory capacity of hLAIR-1 (10).
Interestingly, collagens are high-affinity ligands for LAIR
molecules, and the interaction between LAIR-1 and collagen
directly inhibits immune cell activation in vitro and may
represent a novel mechanism of peripheral immune regula-
tion mediated by the extracellular matrix (ECM) (11).
The role of the co-stimulatory pathway downstream of
immunoreceptor tyrosine-based activating motif (ITAM)-
harboring receptors in osteoclastogenesis has been exten-
sively studied. However, the potential implication of ITIM-
harboring receptors remains unclear, and the existing
literature shows conflicting results. In addition, the involve-
ment of LAIR-1 in OC formation has not yet been studied. In
the pathology of RA, chronic inflammation leads to bone
destruction (12), and OCs is a key player in this process. For
example, in a serum transfer model of inflammatory
arthritis, animals that are unable to produce OCs do not
show evidence of bone resorption despite the presence of
inflammation (13). Therefore, we further investigated the
possibility that LAIR-1 may be involved in the pathological
process of inflammatory RA by modulating osteoclastogen-
esis.
& MATERIALS AND METHODS
Ethics
All procedures were approved by the local ethics
committee, and all of the participants provided written
informed consent.
Regents and mice
All media components were purchased from GIBCO
(Carlsbad, CA, USA). Recombinant cytokines were purchased
from R&D Biosystems, Inc. Bovine collagen II and culture-cell
BSA and TRAP solutions (No. 387) were purchased from
Sigma (St Louis, MO, USA). The functional purified anti-
mouse LAIR-1 monoclonal antibodies (mAbs) and isotype
control Abs were purchased from eBioscience (San Diego, CA,
USA). Human CD14+ monocytes from PBMC were separated
using magnetic MicroBeads (Miltenyi Biotec, Bergisch
Gladbach, Germany). The anti-human antibodies against
CD3, CD20, and CD68 were purchased from Maxin
Biotechnology (Fuzhou, Fuzhou, China). The anti-mouse
LAIR-1 (mLAIR-1) polyclonal antibody, anti-hLAIR-1 anti-
body (9.1C3), and sandwich ELISA kit for detecting soluble
hLAIR-1 were established by our laboratory (14). C57BL/6
mice were purchased from the laboratory animal center at our
university. All of the mice were cared for in accordance with
the institutional guidelines for animal welfare.
Patients
RA patients were selected at random from the Tangdu
Hospital at our university. All of the patients fulfilled the
American College of Rheumatology classification criteria for
RA and had a disease duration of .1 year. In all the RA
patients, disease activity was measured with the Disease
Activity Score 28-joint assessment (DAS28) (15). None of the
patients were treated with TNF-a blocker therapy. Age- and
sex-matched healthy volunteers and osteoarthritis (OA)
patients served as controls. A total of 20–30 ml of whole
blood was collected by venipuncture for routine laboratory
investigations. Sera were isolated from 22 healthy indivi-
duals, 18 OA patients, and 17 RA patients. Meanwhile,
synovial fluids were treated with hyaluronidase type IV at
20 U/ml (Sigma-Aldrich, St. Louis, MO, USA) for 20 min at
37 C˚ to reduce viscosity. The sera and synovial fluids were
stored at -20 C˚ until use. Synovial tissue samples were
obtained from RA patients at the time of surgical treatment.
In vitro osteoclastogenesis and mAb stimulation
The induction of murine OCs in vitro was performed as
previously described (6). Briefly, total murine BM was
flushed from the tibias and femurs of two- to three-week-
old mice, and freshly harvested BM cells were cultured at
56105 cells/ml in minimum essential medium (a-MEM)
with 10% FBS containing 10 ng/ml M-CSF. After two days,
non-adherent BM cells were discarded, and adherent cells
were used as BM monocyte/macrophage lineage cells
(BMMs). The BMMs were further cultured for 6 days in the
presence of 100 ng/ml recombinant mouse receptor
activator of nuclear factor kappa-B ligand (rmRANKL)
and 10 ng/ml macrophage colony-stimulating factor (M-
CSF) to generate mature OCs. For osteoclastogenesis after
mAb stimulation, 96-well flat-bottom plates were coated
overnight at 4 C˚ with commercial anti-mLAIR-1 mAbs or
control Abs at a concentration of 10 mg/ml in phosphate-
buffered saline (PBS). BMMs were plated at 56105 cells/ml
and then cultured as previously described for six days.
The medium and factors were replaced after three days.
For the human OC cultures, peripheral blood CD14+
monocytes were MACS-sorted from healthy volunteers,
according to the guidelines of the ethics committee at our
university. TRAP+ multinuclear cells (MNCs, .3 nuclei)
were counted.
Flow cytometric (FCM) analysis
Rabbit polyclonal antibodies against the mLAIR-1 protein
were prepared by immunization with the mLAIR-1-Fc fusion
protein and were purified from rabbit sera using a Sepharose-
4B affinity column (Pharmacia, Peapack, NJ, USA) coupled
with mLAIR-1-Fc. To analyze the cell surface expression of
mLAIR-1, the cells were incubated with DyLight 649-
conjugated anti-mLAIR-1 polyclonal antibody and appro-
priate isotype controls (Pierce DyLight 649 labeling kit,
Thermo scientific, Rockford, IL, USA). The procedures for
mouse BM cell, BM-derived macrophage (BM-MW), and BM-
derived OC (BM-OC) immunofluorescence staining and
FCM analysis were conducted as previously described (15).
The cells were examined with a flow cytometer (FACS
Calibur, BD, San Jose, CA, USA) and analyzed using the
WinMDI software ver.2.9 (San Diego, CA, USA).
TRAP staining
On day six of the BMM culture, the cells were washed
with PBS and fixed with 4% paraformaldehyde. The
cultures were then stained for TRAP by incubating the cells
in a 0.1 M sodium acetate buffer (pH 5.0) containing
naphthol AS-BI phosphoric acid sodium salt and fast red
ITR salt in the presence of 10 mM sodium tartrate.
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Hematoxylin-eosin (HE) and immunohistochemistry
(IHC) staining
The synovial tissue obtained from RA patients was fixed
in 10% formalin, embedded in paraffin, and stained with
HE. For IHC staining, the Immunocruz staining system
(Santa Cruz) was employed according to the manufacturer’s
instructions. The sections were incubated with anti-hLAIR-1
antibody (9.1C3) or other primary antibodies; negative
controls were performed by replacing the primary antibody
with normal mouse Ig at the same concentration.
Lentiviral transductions
Lenti-X lentiviral expression systems were used to over-
express hLAIR-1 according to the manufacturer’s instruc-
tions (Clontech, Mountain View, CA, USA). Briefly, the
LAIR-1 open reading frame (ORF) was inserted into the
Lenti-X plasmid vector and then co-transfected into Lenti-X
293T cells, using a Lenti-X HTX Packaging Mix, to produce
recombinant lentivirus for target cell infection, as previously
described (16). The resulting lentivirus-containing super-
natants were used to infect healthy human CD14+ mono-
cytes for 6–8 hours. The media were then exchanged with
fresh a-MEM containing 10% FBS. Infected cells were
cultured with 100 ng/ml rhRANKL and 30 ng/ml M-CSF
for seven days, and the cells were harvested for assays.
Statistical analysis
Normally distributed data were analyzed using the
Student’s t-test; otherwise, the Wilcoxon signed rank test
was used. All data were expressed as the mean¡ SEM, and
p,0.05 was considered to be statistically significant. All
statistical tests were performed with the GraphPad Prism
software version 4.0 (GraphPad Software, San Diego, CA,
USA).
& RESULTS
Expression of mLAIR-1 on OCs
To date, the expression of LAIR-1 in the OC system has
not been reported. Therefore, we first investigated the
expression of LAIR-1 on mature OCs. The rabbit anti-
mLAIR-1 polyclonal antibody was generated in our labora-
tory and used for the FCM analysis. Surface mLAIR-1
expression was predominantly detected on BM-MW and
was expressed at a lower level by BM-OCs (Figure 1).
Effect of LAIR-1 mAb on OC formation
To investigate the involvement of LAIR-1 in OC forma-
tion, we next examined whether treatment with LAIR-1
mAb or collagen in the mono-culture system would affect
OC formation. Mouse BMMs were cultured with M-CSF
and RANKL for six days in the presence of commercial
mLAIR-1 mAb, collagen, or control reagents. Note that we
chose bovine collagen II as the ligand for stimulation
because the LAIR-1 molecule interacts in a cross-species
manner with various collagen molecules and recognizes the
conserved Gly-Pro-Hyp repeats present in all collagen
trimers. Figure 2A shows representative photographs of
the effects of this treatment on TRAP+ multinucleated OC
formation. MNC OC formation was significantly decreased
in a mono-culture system of BMMs via the cross-linking of
mLAIR-1 molecules by anti-mLAIR-1 mAb. These data
indicate that LAIR-1 inhibits osteoclastogenesis in vitro
(Figure 2B). However, collagen II, a high-affinity ligand for
LAIR-1, did not significantly inhibit OC differentiation.
LAIR-1-expressing cells in the synovial tissue of RA
patients
Given the importance of LAIR-1 as a co-stimulatory
molecule in murine OC differentiation and function, we
investigated the expression pattern of human LAIR-1 in the
synovial tissue (Figure 3) of five RA patients by IHC. First,
HE staining of the knee joint showed abundant inflamma-
tory cell infiltration at the subsynovial tissues (Figure 3A),
whereas positive staining was not observed in sections
stained with the isotype control (Figure 3B). Anti-human
CD3, CD20, and CD68 antibodies were used to detect the
presence of T cells, B cells, and macrophages (Figures 3C-F).
At the same time, staining with the anti-hLAIR-1 antibody
revealed prominent colocalization with macrophage stain-
ing, which indicated (consistent with our previous results)
that hLAIR-1 is highly expressed in differentiated mature
macrophages.
Determination of soluble hLAIR-1 levels in patients
with OA and RA
Because shedding of surface molecules is a commonly
observed regulatory phenomenon, we developed a sand-
wich ELISA to investigate the presence of soluble hLAIR-1
in the serum and synovial fluid. The characteristics of the
RA patients are summarized in the supplemental material
(Table 1). Of the patients examined, 13 were female and four
were male, and the mean patient age was 50.9¡17.3 years.
The mean age of the healthy volunteers and OA patients
was 51.7¡13.7 and 58.2¡6.4 years, respectively. The mean
erythrocyte sedimentation rate (ESR) of the RA patients was
59.3 mm/h, and the mean DAS28 score was 5.5, indicating
active disease. Overall, 20 of the 22 healthy volunteers
showed detectable levels of serum soluble hLAIR-1 (average
2.72¡1.50 ng/ml, range 0.36–6.33 ng/ml). All of the
patients with OA or RA were sera-soluble hLAIR-1-positive,
with average concentrations of 3.61¡1.64 ng/ml (range 0.2–
6.33 ng/ml) and 7.15¡7.65 ng/ml (range 0.36–30.65 ng/
ml), respectively (Figure 4A).
To explore whether hLAIR-1 is present at sites of
inflammation, we measured soluble hLAIR-1 in the
synovial fluids of patients with RA (n = 13). Soluble
hLAIR-1 levels were compared to those found in the
synovial fluids from patients with OA (n = 14) who suffered
Figure 1 - FCM analysis of cell-surface mLAIR-1 expression in
freshly isolated BM cells BM-Mw, and BM-OC. After differentia-
tion, the cells were stained with anti-mLAIR-1 polyclonal anti-
body (shaded histogram) or isotype control mAb (open
histogram).
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from joint degeneration with no detectable or mild
inflammation, and the soluble hLAIR-1 concentrations in
the synovial fluids from RA patients were significantly
elevated (average 45.8¡24.4 ng/ml, range 13.6–91.2 ng/ml)
compared to those in OA patients (average 22.9¡13.5 ng/ml,
range 9.5–57.3 ng/ml, p,0.05) (Figure 4B). Thus, the
increased soluble hLAIR-1 levels in RA synovial fluid
seem to reflect the local inflammation in the joints of these
patients.
High level of hLAIR-1 expression decreases
osteoclastogenesis in healthy humans ex vivo
To further evaluate the significance of these findings in a
clinical setting, we also assessed whether the hLAIR-1
molecule could negatively stimulate osteoclastogenesis using
monocytes from humans. After culture with 100 ng/ml
rhRANKL and 30 ng/ml M-CSF, a decreased number of
TRAP+ MNCs were formed when hLAIR-1 lentivirus was
added to CD14+ MACS-sorted blood monocytes as compared
to the control group, which was infected with a control
lentivirus (Figure 5). Furthermore, we failed to detect OC
formation when there was no RANKL supplement in the
culture medium (vehicle control). Lentivirus infection
resulted in an average 89% gene transfer rate, as assessed
by PCR (data not shown). These results demonstrated that
the over-expression of hLAIR-1 in an in vitro mono-culture
system negatively affected osteoclastogenesis. Together, our
data reveal that activation of the LAIR-1 pathway inhibits in
vitro osteoclastogenesis in both mice and humans.
& DISCUSSION
LAIR-1 is a receptor for ECM collagens, and the
interaction between LAIR-1 and collagens is of a high
affinity and is dependent on the presence of hydroxyproline
in a post-translational modification uniquely present in Gly-
Pro-Hyp collagen repeats (20,21). However, when we used
collagen II to stimulate mLAIR-1, no significant reduction in
the final yield of TRAP+ MNCs was observed. Collagens are
the most abundant ECM proteins in most animals, and they
can also interact with activatory receptors, such as OSCAR.
Therefore, the integral effect of collagens in controlling
osteoclastogenesis remains unclear.
It is not known whether the tyrosines in the ITIMs of
LAIR-1 become phosphorylated and serve as docking sites
for SHP-1 and SHP-2. However, it has been reported that
LAIR-1 signaling is not impaired in cells deficient for the
SHP-1 and SHP-2 phosphatases; thus, the C-terminal Src
Kinase (Csk) may be the key downstream effector of LAIR-1
in cells where phosphatase activity is limited (17). Because
Csk has been demonstrated as playing a key role in
osteoclastogenesis (although it negatively regulates the
kinase activity of c-Src) we hypothesized that LAIR-1 may
regulate OC formation through Csk, although this must be
further evaluated in subsequent studies (18,19).
Very recently, Meyaard et al. demonstrated that the
synovial fluid levels of soluble hLAIR-1 were significantly
increased in RA patients and that LAIR-2 (soluble, homo-
logous to hLAIR-1) levels in the urine were significantly
correlated with markers of inflammation [23]. Our research
Figure 2 - Effect of mLAIR-1 mAb on OC formation induced by soluble RANKL. OC formation was induced by M-CSF (10 ng/ml) and soluble
RANKL (100 ng/ml) in the mono-culture system of BMMs. (A) Photomicrographs taken from the cultures stained for TRAP after six days of BM
cell culture (magnification,6100) with the basal medium, normal mouse IgG (mIgG), LAIR-1 mAb, BSA, and collagen. (B) Data are expressed as
the number of TRAP+ MNC cells and represent the means¡ SEM (n=3), *p,0.01.
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group is more interested in the relationship between the
level of soluble LAIR-1 and inflammatory arthritis. We
found that the sera levels of soluble hLAIR-1 were
significantly increased in RA patients, and this result is
not fully consistent with Meyaard’s work. We think that the
reason for this difference may be partially due to the patient
samples that we used. All of the patients who participated
in this research were never treated with any corticosteroids
or biological recombinant medicine, such as adalimumab or
etanercept. Moreover, although Meyaard concluded that
LAIR-2 was a more efficient antagonist of the LAIR-collagen
interaction than soluble LAIR-1, LAIR-1 may also play an
important role because the levels of soluble hLAIR-1 are
much higher than those of LAIR-2.
It is well known that many trans-membrane receptors can
be shed from the cell surface and released into the circulation
in soluble form when immune cells are activated. In many
cases, the levels of soluble receptors in the circulation can be
used as markers of disease severity. Using a sandwich ELISA,
we found that the soluble level of hLAIR-1 in sera from
healthy individuals was significantly higher than that in RA
and OA patients. Furthermore, the soluble hLAIR-1 level in
the synovial fluids from RA patients was higher than those in
OA patients. These results indicate that increased hLAIR-1
may be released or shed from the cells of RA patients,
suggesting that the circulating soluble LAIR-1 may regulate
the inhibitory potential of membrane-bound LAIR-1 via
Figure3-HumanLAIR-1immunohistochemistryinkneejointsections
of RA patients. (C-F) The synovial samples obtained by arthroscopic
synovectomy from five RA patients were analyzed by IHC for the
expressionofCD3,CD20,CD68,andhLAIR-1. (AandB)HEandisotype
control staining for IHC are also shown (magnification,6100).
Table 1 - Characteristics of the studied RA patients*.
Patient
Age/
gender DAS28 CRP mg/ml
ESR
mm/h RF U/ml
sCD305
(ng/ml)
1 66/F 5.2 14.3 75 ,20.0 1.11
2 55/F 4.0 4.9 50 ,20.0 4.76
3 71/F 4.1 13.8 75 ,20.0 1.33
4 67/F 3.8 11.7 53 24.0 6.01
5 48/M 7.0 27.6 96 197.0 6.33
6 53/F 5.6 67.5 90 514.0 4.76
7 36/M 6.9 ,3 19 ,20.0 2.02
8 72/M 4.6 9.1 60 ,20.0 4.16
9 43/F 6.7 ,3 73 192.0 30.65
10 54/F 7.2 5.0 106 23.3 4.76
11 42/F 4.4 4.7 26 ,20.0 0.36
12 36/F 7.1 66.4 52 772.0 3.87
13 35/F 3.3 ,3 17 143.0 18.33
14 55/M 7.3 2.3 90 233.0 2.52
15 55/F 4.9 4.1 20 26.8 7.68
16 47/F 6.6 4.7 82 132.0 8.37
17 30/F 4.7 ,3 24 76.3 14.5
*DAS28 = Disease Activity Score 28-joint assessment; CRP = C-reactive
protein (normal ,5 mg/l); ESR = erythrocyte sedimentation rate (normal
,10 mm/h), RF = rheumatoid factor (normal ,60 U/ml).
Figure 4 - Presence of soluble hLAIR-1 in the sera and synovial fluid of patients with RA or OA. Measurements were performed by ELISA,
as described in the Materials and Methods. (A) The Wilcoxon signed rank test indicated a statistically significant elevation of soluble
hLAIR-1 levels in the sera of RA patients compared to healthy controls, *p,0.05. (B) The Wilcoxon signed rank test indicated a
statistically significant elevation of soluble hLAIR-1 levels in the synovial fluid of RA patients compared to OA patients, *p,0.05.
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competition for ligands. However, the OCs in RA patients
may be more prone to induction or activation because of the
lower expression of LAIR-1 on the membrane after shedding.
In this article, we demonstrated the negative regulatory
role of LAIR-1 in osteoclastogenesis both in humans and in
mice. We found that hLAIR-1 is highly expressed by
CD68+macrophages from RA patients and that the levels
of soluble hLAIR-1 in the sera and synovial fluid from RA
patients were significantly greater than those in OA
patients, which was also correlated with the levels of
rheumatoid factor. Collectively, these results suggest that
activated OC differentiation in RA patients may either be
caused by the lower expression of hLAIR-1 (shed from the
cell membrane) or because of the increased expression of
LAIR-1 functional blockers such as soluble hLAIR-1. These
findings support evidence for the regulation of OC forma-
tion by ITIM-harboring Ig-like receptors, which may have
potential clinical significance in RA therapy.
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